184.108.40.206 Acute Exacerbation of ulcerative colitis
Rectal Treatment – for distal ulcerative colitis only (proctitis/proctosigmoiditis)
|Prescribe by brand||Prescribe by Brand|
Mesalazine enema - 1st choice for distal (rectosigmoid) colitis
Salofalk® mesalazine rectal foam (14 doses)
Dose: Mild ulcerative colitis affecting sigmoid colon and rectum, 2 metered applications (mesalazine 2g) into the rectum at bedtime or in 2 divided doses
|Pentasa® Mesalazine Enema (1g/100ml)||Dose: Pentasa® Mesalazine Enema: One enema (1g/100ml) administered at bedtime|
|Mesalazine suppositories 1g Available as:|
Salofalk® 1g suppositories (cost-effective choice)
Dose: Acute mild to moderate ulcerative proctitis, one Salofalk 1g suppository once daily inserted into the rectum
Octasa® 1g suppositories
Dose: Acute mild to moderate proctitis, one Octasa 1g suppository once daily inserted into the rectum
|Prescribe by brand|
Oral mesalazine Available as:
Octasa® M/R tablets 400mg, 800mg: 2.4-4.8g once daily or in divided doses (doses over 2.4g daily in divided doses only); Octasa® M/R tablets 1600mg: 2.4-4.8g once daily or in divided doses (note 1600mg tablets can be given in doses up to 4.8g as a once daily dose)
|Pentasa® M/R tablets 500mg, 1g; sachets 1g, 2g, 4g||Pentasa® M/R tablets: acute treatment, up to 4g daily once daily or in divided doses|
|Salofalk (mesalazine m/r) granules, 1.5g, 3g sachets||Salofalk m/r granules: 1.5-3g once daily, dose preferably taken in the morning|
(Add on therapy if insufficient response to 5-ASA monotherapy)
|Prednisolone tablets 1mg, 5mg||Dose: 30-40mg daily (up to 1mg/kg) for 1 week, reducing by 5mg weekly thereafter according to patient response|
- Refer to CKS and ECCO for further information on the prescribing of aminosalicylates in ulcerative colitis and Crohn’s disease
- Drugs used to maintain or induce remission in inflammatory bowel disease should always be started by a specialist, but they may be continued and monitored by a GP in primary care as per shared care arrangements.
- For acute attacks, prescribers may consider titrating doses according to response whilst awaiting specialist admission.
- Maintenance rectal therapy is an appropriate treatment strategy for rectal disease. Suppositories are the treatment of choice for patients with inflammation confined to the rectum; enemas should be used for more extensive inflammation.
- Foam and liquid appear to be equally effective in treating patients with distal ulcerative colitis. Foam enemas are generally preferred because they are easier to administer and retention is more comfortable. However, liquid enemas are more effective for proximal disease as they travel further. Suppositories are usually better tolerated than enemas.
- Mesalazine enemas are likely to be more effective than steroid enemas. Steroid enemas should be reserved for those patients who do not respond to mesalazine. Please note prednisolone foam enemas are very high cost. Predsol® retention enema 20mg/100ml rectal solution is a cost effective option. If a steroid foam is required, Budenofalk® (budesonide) rectal foam is less expensive than prednisolone foam.
- There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary. If it is necessary to switch a patient to a different brand of mesalazine the patient should be advised to report any changes in symptoms.
- Patient tolerability can vary between mesalazine products therefore it is worth trying a few different products – see BNF for full range of products.
- Acute exacerbation of extensive disease requires systemic corticosteroid.